A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer

The aims of this phase I study were to establish the maximum tolerated dose, safety profile and activity of liposomal daunorubicin, DaunoXome (NeXstar Pharmaceuticals), in the treatment of metastatic breast cancer. DaunoXome was administered intravenously over 2 h in 21 day cycles and doses were inc...

Descripción completa

Detalles Bibliográficos
Autores principales: O'Byrne, K J, Thomas, A L, Sharma, R A, DeCatris, M, Shields, F, Beare, S, Steward, W P
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2002
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364277/
https://www.ncbi.nlm.nih.gov/pubmed/12085249
http://dx.doi.org/10.1038/sj.bjc.6600344

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364277/
https://www.ncbi.nlm.nih.gov/pubmed/12085249
http://dx.doi.org/10.1038/sj.bjc.6600344

Ejemplares similares